The 2006 release by Sandoz of the first biosimilar in the EU helped pave the way for increased access to other biosimilar products across a range of therapy areas1
Biologics are important, but often expensive, medicines used to treat a range of serious diseases. As proven therapeutic alternatives to reference biologics, biosimilars can help to fill an important unmet need by providing expanded options, enhanced affordability for health systems, and increased access to therapy. For this reason, biosimilars represent an innovative solution that can benefit patients and the entire healthcare community by reducing the burden of rising treatment costs.1-4
Adapted from: IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. Parsippany, NJ; March 2016.
*Based on 8 key biologics addressed in this analysis: adalimumab, insulin glargine, etanercept, infliximab, rituximab, pegfilgrastim, trastuzumab, and follitropin alfa.
†The EU5 comprises France, Germany, Italy, Spain, and the UK.
The extent of the savings realized will be dependent on policy development, implementation across all stakeholders, and level of competition.1,5
References: 1. IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. Parsippany, NJ; March 2016. 2. Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111-5117. 3. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012;7(suppl 1):S57-S67. 4. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405-417. 5. Mulcahy AW, Predmore Z, Mattke S; for the RAND Corporation. The cost savings potential of biosimilar drugs in the United States. http://www.rand.org/pubs/perspectives/PE127.html. Published 2014. Accessed September 7, 2016.